Update on Dr. Faustman's Phase-II Trial of BCG
Dr. Faustman's lab has published their Fall 2017 newsletter, which you can read here:
This newsletter includes more information on her research, especially from the 3rd International BCG conference, The BCG Working Group, and the 2nd edition of the BCG and Autoimmunity book she edited.
There are three pieces of new news there:
- The phase-II trial was fully enrolled in Summer of 2017. This is important because we now know when the trial will end. Since this is a five year study, they should finish collecting data in Summer of 2022 and publish before Summer of 2023.
- They have given BCG to the three untreated patients from their phase-I trial, so they will have data from six people to report in the future.
- The lab is going to be recruiting for more studies in the future, so would like to hear from anyone who is interested in participating. No details on future trials were provided.
DILfrequency Trial Completed
There is a lot of research ongoing on IL-2 which is part of the immune system. About 18 months ago, I summarized all this research here:
with an update here:
One of those clinical trials was called "DILfrequency" and that trial has finished, and the results published. The purpose of that trial was to develop the best dosing method of IL-2 which could then be used in future trials. ("Best" in this case, meant a stable and known change in the immune system, which the researchers wanted.) It was successful in terms of telling the researchers what they wanted to know to prepare for future clinical studies.
There are several IL-2 research projects either ongoing or planned to start (including by this group), so I think we'll get a stronger signal in the next few years.
Journal Article: https://www.biorxiv.org/content/early/2017/11/28/223958
publicjoshualevy at gmail dot com
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials, which might be discussed here. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog.